Teriparatide Acetate

Summary

Teriparatide Acetate (CHEMBL1201549) is an approved protein; indicated across 5 conditions including hypoparathyroidism and digeorge syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 5 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201549
Name	Teriparatide Acetate
Type	Protein
Max phase	4

Also known as: Ak-159, Ak159, Parathar, Teriparatide acetate, Teriparatide acetate hydrate, TERIPARATIDE ACETATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypoparathyroidism	3	MONDO:0001220	EFO:0009451
DiGeorge syndrome	3	MONDO:0008564	MONDO:0018923
postmenopausal osteoporosis	2	MONDO:0008159	EFO:0003854
osteoporosis	2	MONDO:0005298	EFO:0003882
psoriasis	2	MONDO:0005083	EFO:1001494

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01551602	PHASE1	COMPLETED	Clinical Study of AK159 in Healthy Postmenopausal Women
NCT01935479	PHASE1	COMPLETED	A Phase I Study of AK159 in Healthy Postmenopausal Women

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).